Similarly, mutations in TP53 and SMAD4 play critical roles in later stages, promoting tumor progression and metastasis sequencing technologies continue to evolve, they are poised to transform clinical practice by offering more precise and personalized treatment options for CRC patients (15, 16). Here, TP53 is linked to neoplasm.